Evidence map›Paper›PMID 41480400›Full record

ArticleWorld journal of stem cells2025

Impact of differentiation protocols on the functionality of mesenchymal stem cells derived from induced pluripotent stem cells.

Nidaa A Ababneh, Enas Alwohoush, Razan AlDiqs, Mohammad A Ismail, Ban Al-Kurdi, Raghda Barham, Renata Al-Atoom, Fairouz Nairat, Sabal Al Hadidi, Suha Whaibi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nidaa A AbabnehCell Therapy Center, University of Jordan, Amman 11942, Jordan. n.ababneh@ju.edu.jo.
Enas AlwohoushCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Razan AlDiqsCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Mohammad A IsmailSouth Australian ImmunoGENomics Cancer Institute, Adelaide Medical School, University of Adelaide, Adelaide 5005, Australia.
Ban Al-KurdiCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Raghda BarhamCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Renata Al-AtoomCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Fairouz NairatCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Sabal Al HadidiCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Suha WhaibiCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Mohammad H GharandouqCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Suzan ZalloumCell Therapy Center, University of Jordan, Amman 11942, Jordan.
Sofian Al ShboulDepartment of Pharmacology and Public Health, Faculty of Medicine, Hashemite University, Zarqa 13133, Jordan.
Talal Al-QaisiDepartment of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates.
Areej AbuhammadDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Amman 11942, Jordan.
Tareq SalehDepartment of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama 329, Bahrain.
Abdalla AwidiCell Therapy Center, University of Jordan, Amman 11942, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe discovery of induced pluripotent stem cells revolutionized regenerative medicine, providing a source for generating induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs).

aimTo evaluate and compare five iMSC differentiation protocols, assessing their efficiency, phenotypic characteristics, and functional properties relative to primary mesenchymal stem cells (MSCs).

methodsFive iMSC differentiation protocols were assessed: SB431542-based differentiation (iMSC1, iMSC3), an iMatrix-free method (iMSC2), growth factor supplementation (iMSC4), and embryoid body formation with retinoic acid (EB-iMSC). iMSC identity was confirmed according to the International Society for Cell & Gene Therapy 2006 criteria, requiring expression of surface markers (CD105, CD73, CD90) and absence of pluripotency markers. Functional assays were conducted to evaluate differentiation potential (osteogenic and adipogenic), proliferation, mitochondrial function, reactive oxygen species, senescence, and migration.

resultsAll iMSC types expressed MSC markers and lacked pluripotency markers. EB-iMSC and iMSC2 showed enhanced osteogenesis (runt-related transcription factor 2;

conclusionWhile all protocols generated functional iMSCs, variations in differentiation, proliferation, and function emphasize the impact of protocol selection. These findings contribute to optimizing iMSC generation for research and clinical applications.

Indexed as

Differentiation protocolsInduced mesenchymal stem cellsInduced pluripotent stem cellsRegenerative medicineTissue engineering

Identifiers

PMID41480400
PMCPMC12754551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.